The largest global pharmaceutical supply chain event—the 2025 Convention on Pharmaceutical Ingredients (CPHI)— concluded on October 30. The theme this year was "Shaping Future Pharma." The Medical and Pharmaceutical Industry Technology and Development Center (PITDC) again organized the Taiwan Pharmaceutical Alliance (TPA) delegation, gathering more than 20 leading Taiwanese pharmaceutical manufacturers, contract research organizations (CROs), and packaging suppliers to form the Taiwan Excellence Pavilion. Supported by government initiatives, the pavilion highlighted the pharmaceutical strengths of Taiwan and its globally competitive supply chain.

The exhibitors this year included Chung Mei Biopharma Co. Ltd., China Chemical & Pharmaceutical Co. Ltd., Pei Li Pharmaceutical Industrial Co. Ltd., Swiss Pharmaceutical Co. Ltd., UBI Pharma Inc., Standard Chem & Pharm. Co. Ltd., Yuanchou Pharma, Yung Shin Pharmaceutical Industrial Co. Ltd., Synmosa Biopharma Corporation, Orient EuroPharma Co. Ltd., Mithra Biotechnology Inc., Ta Fong Pharmaceutical Co. Ltd., Sunny Pharmtech Inc., Taiwan Tasheh Biotech Co. Ltd., Taiwan Biotech Co. Ltd., Syn-Tech Chem & Pharm Co. Ltd., KriSan Biotech Co. Ltd., Panlabs Biologics Inc., and Savior Lifetec Corporation.

Photo credit: PITDC.

PITDC introduced new promotional displays, a dedicated website, and a range of marketing activities at the exhibition to widen the global visibility of the pharmaceutical industry in Taiwan. PITDC is a key partner CPHI that has actively promoted the internationalization of Taiwan's pharma sector, attracting strong interest and substantial visitor traffic to the Taiwan Excellence Pavilion. 

PITDC noted that the pharmaceutical industry has increasingly faced challenges because of intensified competition in the generic drug market, changes in U.S. tariff policies, and global supply chain restructuring. In response, CPHI featured a series of intensive business meetings for TPA members, focusing on high-complexity formulations, emerging targeted therapies, antibody-drug conjugates, and PD-1/PD-L1 products, all of which are experiencing a rise in global demand. These discussions centered on R&D and market collaborations as well as exploring opportunities for drug approval, generic drug licensing, CDMO/CMO    partnerships, and strategies for expanding into new markets with international partners.

The patents of numerous branded drugs worldwide will expire starting in 2030. Taiwanese companies can strengthen their competitiveness in the global generic drug market and further enhance Taiwan's role in the international pharmaceutical supply chain by the early establishment of partnerships at international exhibitions and appropriately identifying suitable market entry opportunities.

The CPHI has evolved into a global hub for collaboration and networking across the pharmaceutical industry and supply chain since its inception in 1990 in Frankfurt. The exhibition covers eight major sectors, such as active pharmaceutical ingredients, formulations, pharmaceutical packaging, machinery and equipment, CROs, and CDMOs, attracting over 280,000 industry professionals worldwide each year.

Germany has is recognized for its precision manufacturing, strong R&D, and appropriate government policies. Germany is thus a central hub for global pharmaceutical technology collaboration and export activities.

The CPHI added new areas for AI-driven pharmaceutical technologies, cold chain supply and logistics, and cleanroom manufacturing equipment in 2025. These fields highlight the accelerating shift in the global pharmaceutical industry toward automation, high-quality production, and fully integrated, compliance-focused supply chains.

PITDC will continue to expand Taiwan's presence in global markets and actively promote the integration of the Taiwanese pharmaceutical industry with international markets. PITDC aims to strengthen the global competitiveness of Taiwanese pharmaceutical companies through accelerating technological innovation and industry upgrades. PITDC will also focus on optimizing export strategies to support the sustainable growth of Taiwan’s pharmaceutical sector and maximize its impact in the global market.

Photo credit: PITDC.

Edited by Alice Peng, Globalbio.